Clinical Benefits

• The combination of 270 mg of citrus bioflavonoids and 18 mg of tocotrienols, has been shown to impact total cholesterol by an average of 25% over 4 weeks and 27% over 12 weeks¹: Three studies including a double blind, randomised clinical trial plus two open-label trials demonstrated significant reductions in total cholesterol, triglycerides and LDL:HDL ratio (Figure One).¹

Figure One: Citrus Bioflavonoids and Tocotrienol Combination Impact Cholesterol in a Clinical Trial with 120 subjects.

• Key mechanisms include HMG-CoA reductase inhibition, reduction of apolipoprotein-B100 secretion and modulation of hepatic LDL receptors.^2,3 Specifically, the polymethoxyflavones tangeretin and nobiletin, suppress the hepatic secretion of ApoB and increase LDL receptor synthesis.^4,2 is an exclusive extract of citrus bioflavonoids containing at least 11.5 mg of tangeretin and 10 mg nobiletin per dose.
• Tocotrienols inhibit the production of HMGCoA reductase but support endogenous CoQ10 production via induction of the enzyme geranylgeranyl pyrophosphate (GGPP)². In vitro research shows an 80% inhibition of HMG-CoA reductase by decreasing transcription efficiency and enhancing degradation, unlike most HMG-CoA reductase inhibitors which block the mevalonate pathway by up to 99%.⁵

Figure Two: Ingredients in CholCare act upon multiple points within the Mevalonate Pathway.